Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT
-
- Sung Won Choi
- Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
-
- Thomas Braun
- Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI;
-
- Israel Henig
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
-
- Erin Gatza
- Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
-
- John Magenau
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
-
- Brian Parkin
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
-
- Attaphol Pawarode
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
-
- Mary Riwes
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
-
- Greg Yanik
- Department of Pediatrics, Michigan Medicine, Ann Arbor, MI;
-
- Charles A. Dinarello
- Department of Medicine, University of Colorado, Aurora, CO; and
-
- Pavan Reddy
- Department of Medicine, Michigan Medicine, Ann Arbor, MI;
説明
<jats:title>Key Points</jats:title> <jats:p>Grade 2 to 4 acute GVHD in URD HCT patients who received vorinostat and tacrolimus/methotrexate after myeloablative conditioning was 22%. HDAC inhibition with vorinostat shows potential efficacy for GVHD prevention and should be investigated in a randomized phase 3 trial.</jats:p>
収録刊行物
-
- Blood
-
Blood 130 (15), 1760-1767, 2017-10-12
American Society of Hematology